TY - JOUR AU - Slamon, D. J. AU - Clark, G. M. AU - Wong, S. G. AU - Levin, W. J. AU - Ullrich, A. AU - McGuire, W. L. PY - 1987 DA - 1987// TI - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene JO - Science VL - 235 UR - https://doi.org/10.1126/science.3798106 DO - 10.1126/science.3798106 ID - Slamon1987 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Procter, M. AU - Leyland-Jones, B. AU - Goldhirsch, A. AU - Untch, M. AU - Smith, I. PY - 2005 DA - 2005// TI - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa052306 DO - 10.1056/NEJMoa052306 ID - Piccart-Gebhart2005 ER - TY - JOUR AU - Hurvitz, S. A. AU - Dirix, L. AU - Kocsis, J. AU - Bianchi, G. V. AU - Lu, J. AU - Vinholes, J. PY - 2013 DA - 2013// TI - Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.9694 DO - 10.1200/JCO.2012.44.9694 ID - Hurvitz2013 ER - TY - JOUR AU - Baselga, J. AU - Gelmon, K. A. AU - Verma, S. AU - Wardley, A. AU - Conte, P. AU - Miles, D. PY - 2010 DA - 2010// TI - Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.2024 DO - 10.1200/JCO.2009.24.2024 ID - Baselga2010 ER - TY - JOUR AU - Verma, S. AU - Miles, D. AU - Gianni, L. AU - Krop, I. E. AU - Welslau, M. AU - Baselga, J. PY - 2012 DA - 2012// TI - Trastuzumab emtansine for HER2-positive advanced breast cancer JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1209124 DO - 10.1056/NEJMoa1209124 ID - Verma2012 ER - TY - JOUR AU - Geyer, C. E. AU - Forster, J. AU - Lindquist, D. AU - Chan, S. AU - Romieu, C. G. AU - Pienkowski, T. PY - 2006 DA - 2006// TI - Lapatinib plus capecitabine for HER2-positive advanced breast cancer JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa064320 DO - 10.1056/NEJMoa064320 ID - Geyer2006 ER - TY - JOUR AU - O’Donovan, N. AU - Byrne, A. T. AU - O’Connor, A. E. AU - McGee, S. AU - Gallagher, W. M. AU - Crown, J. PY - 2011 DA - 2011// TI - Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells JO - Investig New Drugs VL - 29 UR - https://doi.org/10.1007/s10637-010-9415-5 DO - 10.1007/s10637-010-9415-5 ID - O’Donovan2011 ER - TY - JOUR AU - Guarneri, V. AU - Frassoldati, A. AU - Bottini, A. AU - Cagossi, K. AU - Bisagni, G. AU - Sarti, S. PY - 2012 DA - 2012// TI - Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.0823 DO - 10.1200/JCO.2011.39.0823 ID - Guarneri2012 ER - TY - JOUR AU - Untch, M. AU - Loibl, S. AU - Bischoff, J. AU - Eidtmann, H. AU - Kaufmann, M. AU - Blohmer, J. U. PY - 2012 DA - 2012// TI - Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70397-7 DO - 10.1016/S1470-2045(11)70397-7 ID - Untch2012 ER - TY - JOUR AU - Minckwitz, G. AU - Schneeweiss, A. AU - Loibl, S. AU - Salat, C. AU - Denkert, C. AU - Rezai, M. PY - 2014 DA - 2014// TI - Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70160-3 DO - 10.1016/S1470-2045(14)70160-3 ID - Minckwitz2014 ER - TY - JOUR AU - Baselga, J. AU - Bradbury, I. AU - Eidtmann, H. AU - Cosimo, S. AU - Azambuja, E. AU - Aura, C. PY - 2012 DA - 2012// TI - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial JO - Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(11)61847-3 DO - 10.1016/S0140-6736(11)61847-3 ID - Baselga2012 ER - TY - JOUR AU - Robidoux, A. AU - Tang, G. AU - Rastogi, P. AU - Geyer, C. E. AU - Azar, C. A. AU - Atkins, J. N. PY - 2013 DA - 2013// TI - Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70411-X DO - 10.1016/S1470-2045(13)70411-X ID - Robidoux2013 ER - TY - JOUR AU - Bonnefoi, H. AU - Jacot, W. AU - Saghatchian, M. AU - Moldovan, C. AU - Venat-Bouvet, L. AU - Zaman, K. PY - 2015 DA - 2015// TI - Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdu551 DO - 10.1093/annonc/mdu551 ID - Bonnefoi2015 ER - TY - STD TI - Crown JL, Keane M, Kennedy J, O’Reilly S, Kelly C, O’Connor M, et al. Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05 [abstract]. Cancer Res. 2013;73(24 Suppl):Abstract P4-12-25. doi:10.1158/0008-5472.SABCS13-P4-12-25. ID - ref14 ER - TY - JOUR AU - Hennessy, B. T. AU - Smith, D. L. AU - Ram, P. T. AU - Lu, Y. AU - Mills, G. B. PY - 2005 DA - 2005// TI - Exploiting the PI3K/AKT pathway for cancer drug discovery JO - Nat Rev Drug Discov VL - 4 UR - https://doi.org/10.1038/nrd1902 DO - 10.1038/nrd1902 ID - Hennessy2005 ER - TY - JOUR AU - Bachman, K. E. AU - Argani, P. AU - Samuels, Y. AU - Silliman, N. AU - Ptak, J. AU - Szabo, S. PY - 2004 DA - 2004// TI - The PIK3CA gene is mutated with high frequency in human breast cancers JO - Cancer Biol Ther VL - 3 UR - https://doi.org/10.4161/cbt.3.8.994 DO - 10.4161/cbt.3.8.994 ID - Bachman2004 ER - TY - JOUR AU - Stemke-Hale, K. AU - Gonzalez-Angulo, A. M. AU - Lluch, A. AU - Neve, R. M. AU - Kuo, W. L. AU - Davies, M. PY - 2008 DA - 2008// TI - An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6854 DO - 10.1158/0008-5472.CAN-07-6854 ID - Stemke-Hale2008 ER - TY - JOUR AU - Berns, K. AU - Horlings, H. M. AU - Hennessy, B. T. AU - Madiredjo, M. AU - Hijmans, E. M. AU - Beelen, K. PY - 2007 DA - 2007// TI - A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer JO - Cancer Cell VL - 12 UR - https://doi.org/10.1016/j.ccr.2007.08.030 DO - 10.1016/j.ccr.2007.08.030 ID - Berns2007 ER - TY - JOUR AU - O’Brien, N. A. AU - Browne, B. C. AU - Chow, L. AU - Wang, Y. AU - Ginther, C. AU - Arboleda, J. PY - 2010 DA - 2010// TI - Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-09-1171 DO - 10.1158/1535-7163.MCT-09-1171 ID - O’Brien2010 ER - TY - JOUR AU - Elster, N. AU - Collins, D. M. AU - Toomey, S. AU - Crown, J. AU - Eustace, A. J. AU - Hennessy, B. T. PY - 2015 DA - 2015// TI - HER2-family signalling mechanisms, clinical implications and targeting in breast cancer JO - Breast Cancer Res Treat VL - 149 UR - https://doi.org/10.1007/s10549-014-3250-x DO - 10.1007/s10549-014-3250-x ID - Elster2015 ER - TY - JOUR AU - Gao, J. AU - Aksoy, B. A. AU - Dogrusoz, U. AU - Dresdner, G. AU - Gross, B. AU - Sumer, S. O. PY - 2013 DA - 2013// TI - Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal JO - Sci Signal VL - 6 UR - https://doi.org/10.1126/scisignal.2004088 DO - 10.1126/scisignal.2004088 ID - Gao2013 ER - TY - JOUR AU - Cerami, E. AU - Gao, J. AU - Dogrusoz, U. AU - Gross, B. E. AU - Sumer, S. O. AU - Aksoy, B. A. PY - 2012 DA - 2012// TI - The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0095 DO - 10.1158/2159-8290.CD-12-0095 ID - Cerami2012 ER - TY - JOUR AU - Djordjevic, B. AU - Hennessy, B. T. AU - Li, J. AU - Barkoh, B. A. AU - Luthra, R. AU - Mills, G. B. PY - 2012 DA - 2012// TI - Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing JO - Mod Pathol VL - 25 UR - https://doi.org/10.1038/modpathol.2011.208 DO - 10.1038/modpathol.2011.208 ID - Djordjevic2012 ER - TY - JOUR AU - Piccart-Gebhart, M. AU - Holmes, E. AU - Baselga, J. AU - Azambuja, E. AU - Dueck, A. C. AU - Viale, G. PY - 2016 DA - 2016// TI - Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.62.1797 DO - 10.1200/JCO.2015.62.1797 ID - Piccart-Gebhart2016 ER - TY - JOUR AU - Engelman, J. A. PY - 2009 DA - 2009// TI - Targeting PI3K signalling in cancer: opportunities, challenges and limitations JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2664 DO - 10.1038/nrc2664 ID - Engelman2009 ER - TY - JOUR AU - Brugge, J. AU - Hung, M. C. AU - Mills, G. B. PY - 2007 DA - 2007// TI - A new mutational AKTivation in the PI3K pathway JO - Cancer Cell VL - 12 UR - https://doi.org/10.1016/j.ccr.2007.07.014 DO - 10.1016/j.ccr.2007.07.014 ID - Brugge2007 ER - TY - JOUR AU - Herter-Sprie, G. S. AU - Greulich, H. AU - Wong, K. K. PY - 2013 DA - 2013// TI - Activating mutations in ERBB2 and their impact on diagnostics and treatment JO - Front Oncol VL - 3 UR - https://doi.org/10.3389/fonc.2013.00086 DO - 10.3389/fonc.2013.00086 ID - Herter-Sprie2013 ER - TY - JOUR AU - Jensen, J. D. AU - Knoop, A. AU - Laenkholm, A. V. AU - Grauslund, M. AU - Jensen, M. B. AU - Santoni-Rugiu, E. PY - 2012 DA - 2012// TI - PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mdr546 DO - 10.1093/annonc/mdr546 ID - Jensen2012 ER - TY - JOUR AU - Loi, S. AU - Michiels, S. AU - Lambrechts, D. AU - Fumagalli, D. AU - Claes, B. AU - Kellokumpu-Lehtinen, P. L. PY - 2013 DA - 2013// TI - Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer JO - J Natl Cancer Inst VL - 105 UR - https://doi.org/10.1093/jnci/djt121 DO - 10.1093/jnci/djt121 ID - Loi2013 ER - TY - JOUR AU - Chandarlapaty, S. AU - Sakr, R. A. AU - Giri, D. AU - Patil, S. AU - Heguy, A. AU - Morrow, M. PY - 2012 DA - 2012// TI - Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1785 DO - 10.1158/1078-0432.CCR-12-1785 ID - Chandarlapaty2012 ER - TY - JOUR AU - Elster, N. AU - Cremona, M. AU - Morgan, C. AU - Toomey, S. AU - Carr, A. AU - O’Grady, A. PY - 2015 DA - 2015// TI - A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib JO - Breast Cancer Res Treat VL - 149 UR - https://doi.org/10.1007/s10549-014-3239-5 DO - 10.1007/s10549-014-3239-5 ID - Elster2015 ER - TY - JOUR AU - Majewski, I. J. AU - Nuciforo, P. AU - Mittempergher, L. AU - Bosma, A. J. AU - Eidtmann, H. AU - Holmes, E. PY - 2015 DA - 2015// TI - PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.55.2158 DO - 10.1200/JCO.2014.55.2158 ID - Majewski2015 ER - TY - JOUR AU - Dave, B. AU - Migliaccio, I. AU - Gutierrez, M. C. AU - Wu, M. F. AU - Chamness, G. C. AU - Wong, H. PY - 2011 DA - 2011// TI - Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2009.27.7814 DO - 10.1200/JCO.2009.27.7814 ID - Dave2011 ER - TY - JOUR AU - Guarneri, V. AU - Dieci, M. V. AU - Frassoldati, A. AU - Maiorana, A. AU - Ficarra, G. AU - Bettelli, S. PY - 2015 DA - 2015// TI - Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer JO - Oncologist VL - 20 UR - https://doi.org/10.1634/theoncologist.2015-0138 DO - 10.1634/theoncologist.2015-0138 ID - Guarneri2015 ER - TY - JOUR AU - Loibl, S. AU - Majewski, I. AU - Guarneri, V. AU - Nekljudova, V. AU - Holmes, E. AU - Bria, E. PY - 2016 DA - 2016// TI - PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw197 DO - 10.1093/annonc/mdw197 ID - Loibl2016 ER - TY - JOUR AU - Eichhorn, P. J. AU - Gili, M. AU - Scaltriti, M. AU - Serra, V. AU - Guzman, M. AU - Nijkamp, W. PY - 2008 DA - 2008// TI - Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1740 DO - 10.1158/0008-5472.CAN-08-1740 ID - Eichhorn2008 ER - TY - JOUR AU - Nagata, Y. AU - Lan, K. H. AU - Zhou, X. AU - Tan, M. AU - Esteva, F. J. AU - Sahin, A. A. PY - 2004 DA - 2004// TI - PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients JO - Cancer Cell VL - 6 UR - https://doi.org/10.1016/j.ccr.2004.06.022 DO - 10.1016/j.ccr.2004.06.022 ID - Nagata2004 ER - TY - JOUR AU - Loibl, S. AU - Darb-Esfahani, S. AU - Huober, J. AU - Klimowicz, A. AU - Furlanetto, J. AU - Lederer, B. PY - 2016 DA - 2016// TI - Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-0965 DO - 10.1158/1078-0432.CCR-15-0965 ID - Loibl2016 ER - TY - JOUR AU - Nuciforo, P. G. AU - Aura, C. AU - Holmes, E. AU - Prudkin, L. AU - Jimenez, J. AU - Martinez, P. PY - 2015 DA - 2015// TI - Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv175 DO - 10.1093/annonc/mdv175 ID - Nuciforo2015 ER - TY - JOUR AU - Pao, W. AU - Miller, V. AU - Zakowski, M. AU - Doherty, J. AU - Politi, K. AU - Sarkaria, I. PY - 2004 DA - 2004// TI - EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0405220101 DO - 10.1073/pnas.0405220101 ID - Pao2004 ER - TY - JOUR AU - Kris, M. G. AU - Camidge, D. R. AU - Giaccone, G. AU - Hida, T. AU - Li, B. T. AU - O’Connell, J. PY - 2015 DA - 2015// TI - Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv186 DO - 10.1093/annonc/mdv186 ID - Kris2015 ER - TY - JOUR AU - Prickett, T. D. AU - Agrawal, N. S. AU - Wei, X. AU - Yates, K. E. AU - Lin, J. C. AU - Wunderlich, J. R. PY - 2009 DA - 2009// TI - Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 JO - Nat Genet VL - 41 UR - https://doi.org/10.1038/ng.438 DO - 10.1038/ng.438 ID - Prickett2009 ER - TY - JOUR AU - Garrett, J. T. AU - Olivares, M. G. AU - Rinehart, C. AU - Granja-Ingram, N. D. AU - Sanchez, V. AU - Chakrabarty, A. PY - 2011 DA - 2011// TI - Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1016140108 DO - 10.1073/pnas.1016140108 ID - Garrett2011 ER - TY - JOUR AU - Rexer, B. N. AU - Ghosh, R. AU - Narasanna, A. AU - Estrada, M. V. AU - Chakrabarty, A. AU - Song, Y. PY - 2013 DA - 2013// TI - Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1038 DO - 10.1158/1078-0432.CCR-13-1038 ID - Rexer2013 ER -